Virtu Financial LLC Purchases Shares of 10,105 scPharmaceuticals Inc. (NASDAQ:SCPH)

Virtu Financial LLC acquired a new position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,105 shares of the company’s stock, valued at approximately $46,000.

Several other large investors have also modified their holdings of SCPH. Suvretta Capital Management LLC purchased a new stake in scPharmaceuticals in the third quarter valued at $9,343,000. Rubric Capital Management LP increased its position in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares in the last quarter. King Luther Capital Management Corp increased its position in shares of scPharmaceuticals by 51.8% during the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after purchasing an additional 752,005 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of scPharmaceuticals by 84.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after purchasing an additional 357,171 shares during the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of scPharmaceuticals in the 2nd quarter valued at about $1,544,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH opened at $3.39 on Friday. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.71. The stock has a market capitalization of $169.64 million, a price-to-earnings ratio of -1.78 and a beta of 0.14. The company has a 50-day simple moving average of $3.81 and a 200-day simple moving average of $4.34. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

Analysts Set New Price Targets

Several research firms have commented on SCPH. Craig Hallum cut their price target on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.